These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 28185715)

  • 1. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Yabiku K; Mutoh A; Miyagi K; Takasu N
    Clin Ther; 2017 Mar; 39(3):558-566. PubMed ID: 28185715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Hooshmand Gharabagh L; Shargh A; Mohammad Hosseini Azar MR; Esmaeili A
    Clin Res Hepatol Gastroenterol; 2024 Mar; 48(3):102279. PubMed ID: 38159676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
    Gupta AK; Bray GA; Greenway FL; Martin CK; Johnson WD; Smith SR
    J Diabetes Complications; 2010; 24(5):289-96. PubMed ID: 19577936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.
    Attaran F; Emami S; Sohrabi M; Malek M; Ajdarkosh H; Khoonsari M; Ismail-Beigi F; Khamseh ME
    BMC Gastroenterol; 2023 Sep; 23(1):327. PubMed ID: 37742004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Euh W; Lim S; Kim JW
    Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
    Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
    Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD).
    Adiwidjaja J; Spires J; Brouwer KLR
    Pharm Res; 2024 Mar; 41(3):441-462. PubMed ID: 38351228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin improves nonalcoholic fatty liver disease in db/db mice by inhibiting ferroptosis.
    Zhang T; Wang MY; Wang GD; Lv QY; Huang YQ; Zhang P; Wang W; Zhang Y; Bai YP; Guo LQ
    Eur J Pharmacol; 2024 Mar; 966():176341. PubMed ID: 38244761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Zhang R; Cheng K; Xu S; Li S; Zhou Y; Zhou S; Kong R; Li L; Li J; Feng J; Wu L; Liu T; Xia Y; Lu J; Guo C; Zhou Y
    Gastroenterol Res Pract; 2017; 2017():8491742. PubMed ID: 28133479
    [No Abstract]   [Full Text] [Related]  

  • 11. CT Quantitation and Prediction of the Risk of Type 2 Diabetes Mellitus in Non-Obese Patients with Pancreatic Fatty Infiltration.
    Tang Y; Wei Z; Li N; Jiang C; Liang C; Sun L; Tian L; Jin Z; Wu Z; Sun H
    Diabetes Metab Syndr Obes; 2024; 17():2619-2625. PubMed ID: 38974951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMR transporters meet the challenge of metformin metabolites.
    Short B
    J Gen Physiol; 2024 Mar; 156(3):. PubMed ID: 38324209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of pioglitazone and simvastatin on urinary liver-type fatty acid-binding protein concentration in diabetic patients with microalbuminuria.
    Wei J; Ma C; Li YM
    Diabetologia; 2007 May; ():. PubMed ID: 17520237
    [No Abstract]   [Full Text] [Related]  

  • 14. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
    Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
    Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.
    Dei Cas A; Spigoni V; Cito M; Aldigeri R; Ridolfi V; Marchesi E; Marina M; Derlindati E; Aloe R; Bonadonna RC; Zavaroni I
    Cardiovasc Diabetol; 2017 Feb; 16(1):27. PubMed ID: 28231835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
    Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
    Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
    Gilbert RE; Mende C; Vijapurkar U; Sha S; Davies MJ; Desai M
    Diabetes Ther; 2017 Apr; 8(2):451-458. PubMed ID: 28197834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
    Kazda CM; Frias J; Foga I; Cui X; Guzman CB; Garhyan P; Heilmann C; Yang JA; Hardy TA
    Diabetes Obes Metab; 2017 Aug; 19(8):1071-1077. PubMed ID: 28191913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.